The Renaissance of Psychedelics
Psychedelics have seen a resurgence in public interest – not merely among users looking for a happy high, but also among researchers who are looking into potential health benefits of this particular category of drugs.
“Psychedelics, the word itself, means mind-manifesting and mind-revealing”, explains Robin Carhart-Harris, Head of the Centre for Psychedelic Research at the Imperial College of London. “So that’s a hint into perhaps what’s special about the properties that they can make visible to consciousness aspects of our minds that otherwise we can’t see.”
In this DLD Munich 2020 panel discussion, he was joined by investor Christian Angermayer (Apeiron Investment Group), Cristiana Falcone (World Economic Forum), Anne Philippi (The New Health Club) and moderator Jörg Rohleder to chat about the implications of psychedelics on psychotherapy and society.
Carhart-Harris explained how psychedelic therapy can offer a more holistic approach to treatment. He also addressed the risks of taking psychedelics. “It would take a huge dose of it for it to be in anyway threatening to life”, he said.
The New Health Club
Anne Philippi is the founder of The New Health Club, a lifestyle platform for psychedelics, exploring the emerging culture of neural awareness.
JMCMRJ Sorrell Foundation
Cristiana Falcone has over 20 years of experience designing and implementing digital transformation, partnership and business development strategies working directly with the leadership at global corporations (SONY, Shell, Revlon), international governmental organizations (ILO, IFAD, FAO, UNDCCP, IADB) and the media industry.
Apeiron Investment Group
Christian Angermayer is an entrepreneur and investor and the founder of Apeiron Investment Group, which focuses on financial services (especially fintech and crypto assets), technology, life sciences, media & entertainment and real estate & prop-tech.
Imperial College London
Robin founded the Centre for Psychedelic Research at Imperial College London in April 2019, the first of its kind in the world, and has an honorary position with the University of Oxford. Dr. Harris has designed human brain imaging studies with LSD, psilocybin, MDMA and DMT, a clinical trial of psilocybin for treatment-resistant depression.